Schering AG

Schering AG of Berlin and Avid Radiopharmaceuticals Inc. of Philadelphia are collaborating to develop diagnostic imaging agents for Alzheimer’s. The compounds, made by Avid, bind to amyloid plaques in the brain, which are thought to cause the disease. The compounds can be used with noninvasive imaging techniques such as PET. Under the agreement, Schering has the option to assume exclusive rights for the development and commercialization of such compounds for use with PET.





LATEST NEWS

• AmeriCOM Adds President and CEO: People in the News: 5/1/24
  May 1, 2024
• Machine Learning Pushes High-Power Lasing Limits
  May 1, 2024
• IPG Names Industry Veteran Mark Gitin CEO
  Apr 30, 2024
• 16th Biannual Optatec Conference Continues in Frankfurt
  Apr 30, 2024
• Celestial Surface Mapping Tech Combines Established Techniques
  Apr 30, 2024
• TSMC Partnerships Target Integrated Photonics Capabilities
  Apr 30, 2024
• CLEO Heads to the East Coast
  Apr 29, 2024
• Qubits Could be Stored in Flash-Like Memory
  Apr 29, 2024